Truist Financial Initiates Caribou Biosciences(CRBU.US) With Buy Rating
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Caribou Biosciences (CRBU) Receives a Buy From H.C. Wainwright
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Caribou Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Caribou Biosciences Analyst Ratings
RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target
Strategic Focus and Financial Runway Extension Bolster Caribou Biosciences' Buy Rating
Caribou Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
RBC Cuts Price Target on Caribou Biosciences to $14 From $19, Maintains Outperform, Speculative Risk
Caribou Biosciences Analyst Ratings
Evercore ISI Downgrades Caribou Biosciences to In-Line Rating With $3 Price Target
Analysts Conflicted on These Healthcare Names: AstraZeneca (GB:AZN), Sartorius (GB:0NIR) and Caribou Biosciences (CRBU)
Truist Securities: Maintains Caribou Biosciences (CRBU.US) rating, adjusted from buy to buy rating, with a target price of $19.00.
Caribou Biosciences Analyst Ratings
Truist Financial Releases a Buy Rating on Caribou Biosciences (CRBU)
HC Wainwright & Co. : The Caribbean Biosciences (CRBU.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $24.00.
Caribou Biosciences Analyst Ratings